Abstract:BackgroundBoth age‐related and congenital volume deficiencies may be addressed through the injection of hyaluronic acid (HA) fillers. Deep injection provides structural support, more superficial fat‐tissue injection mediates contouring, and superficial intradermal use of HA filler and/or onabotulinumtoxinA may be used for refinement.AimsTo evaluate the clinical efficacy, patient satisfaction, and safety of the MD Codes approach as a proposed standardized methodology for full‐face rejuvenation.MethodsThis was a… Show more
“…For those familiar with MD Codes filler injection technique, the deep fat compartments relate to CK3 (SOOF) and CK1* (Sub-SMAS along the zygoma), both of which are accessed with a cannula; while NL1 (Piriform space) and T1 (temple) are accessed with a needle. 67 HA is postulated to have regenerative capacity when injected into the tissues, 40 so it will be interesting to see if future studies show an improvement in DMCFC elasticity after repeated injections of volumizing HA fillers. Figure 5 Treatment description: Lateral Cheekbones: Juvederm Voluma, 0.1mL in 3 points each side, on periosteum with a needle; Pre-auricular area: Juvederm Voluma, 0.7mL each side, in the subcutaneous layer using a cannula; Malar area- Juvederm Voluma, 0.5mL each side, in the deep malar fat pad, using a cannula; Malar area: Juvederm Volift 0.5mL each side, in SOOF layer, using a cannula; Temporal fossa- Juvederm Voluma, 0.5mL each side, on periosteum using a needle; Labiomental crease- Juvederm Voluma, 0.7mL each side, in the subcutaneous layer using a cannula; Chin apex/pogonion: Juvederm Volux, 0.3mL each side, subcutaneous/intramuscular (mentalis muscle) using a needle; Medial to marionette lines- Juvederm Voluma, 0.5mL each side, in the subcutaneous layer using a cannula; Jawline- Juvederm Voluma, 1mL each side, in the subcutaneous layer of the pre-jowl sulcus and medial jawline using a cannula; Nasolabial folds- Juvederm Volift, 0.5mL each side, in the subcutaneous layer using a cannula.…”
“…For those familiar with MD Codes filler injection technique, the deep fat compartments relate to CK3 (SOOF) and CK1* (Sub-SMAS along the zygoma), both of which are accessed with a cannula; while NL1 (Piriform space) and T1 (temple) are accessed with a needle. 67 HA is postulated to have regenerative capacity when injected into the tissues, 40 so it will be interesting to see if future studies show an improvement in DMCFC elasticity after repeated injections of volumizing HA fillers. Figure 5 Treatment description: Lateral Cheekbones: Juvederm Voluma, 0.1mL in 3 points each side, on periosteum with a needle; Pre-auricular area: Juvederm Voluma, 0.7mL each side, in the subcutaneous layer using a cannula; Malar area- Juvederm Voluma, 0.5mL each side, in the deep malar fat pad, using a cannula; Malar area: Juvederm Volift 0.5mL each side, in SOOF layer, using a cannula; Temporal fossa- Juvederm Voluma, 0.5mL each side, on periosteum using a needle; Labiomental crease- Juvederm Voluma, 0.7mL each side, in the subcutaneous layer using a cannula; Chin apex/pogonion: Juvederm Volux, 0.3mL each side, subcutaneous/intramuscular (mentalis muscle) using a needle; Medial to marionette lines- Juvederm Voluma, 0.5mL each side, in the subcutaneous layer using a cannula; Jawline- Juvederm Voluma, 1mL each side, in the subcutaneous layer of the pre-jowl sulcus and medial jawline using a cannula; Nasolabial folds- Juvederm Volift, 0.5mL each side, in the subcutaneous layer using a cannula.…”
“…Injection points were based on those described in the standardized MD Codes™ approach, 10 , 11 and the acronyms used are from this method: Jw1, mandibular angle; Jw2, pre‐auricular area; Jw3, mandibular body; Jw4, lower pre‐jowl; Jw5, lower anterior chin; C1, labiomental angle; C2, chin apex; C3, anterior chin; C4, anterior chin / Pogonion; C5, lateral lower chin; and C6, lateral chin. A 25G 38‐mm cannula was used for all points except C2‐3–4–5 and Jw1, for which a 27G 13 mm needle was preferred.…”
Men represent only a small proportion of the overall patient population in aesthetic medicine. Indeed, in 2018, only around 10% of minimally invasive, non-surgical facial treatments using hyaluronic acid (HA) fillers or botulinum neurotoxin type A (BoNTA) were given to male patients. 1,2 Men are also under-represented in clinical trials of these products. 3 However, growing numbers of males are consulting with practitioners about the possibility of facial aesthetic treatments. 4,5 This apparent increase in popularity may be driven by several factors, including the following: greater desire among many men to look
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.